Trials / Completed
CompletedNCT06898424
Impact of Ketoflex 12/3 Diet on Early-to-Mid Stage Alzheimer's Progression
Effects of Concurrent Plant-Based Ketogenic Diet and Intermittent Fasting (Ketoflex 12/3) on the Clinical Progression of Early-to-Mid Stage Alzheimer's Dementia
- Status
- Completed
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 60 (actual)
- Sponsor
- Prof. Lutfu Hanoglu, MD · Academic / Other
- Sex
- All
- Age
- 50 Years – 85 Years
- Healthy volunteers
- Not accepted
Summary
This study investigates the effects of the Ketoflex 12/3 diet on the clinical progression of early-to-mid stage Alzheimer's disease. The study evaluates cognitive function, metabolic changes, and overall health outcomes in participants following the Ketoflex 12/3 dietary protocol.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BEHAVIORAL | Ketoflex 12/3 Diet | plant-based ketogenic diet combined with intermittent fasting (12/3) |
Timeline
- Start date
- 2024-03-01
- Primary completion
- 2024-09-30
- Completion
- 2024-10-31
- First posted
- 2025-03-27
- Last updated
- 2026-03-24
Locations
1 site across 1 country: Turkey (Türkiye)
Source: ClinicalTrials.gov record NCT06898424. Inclusion in this directory is not an endorsement.